- 同
- Campath-1 H
- 同
- Campath-1 H
WordNet
- not in favor of (an action or proposal etc.)
- a person who is opposed (to an action or policy or practice etc.); "the antis smelled victory after a long battle"
- social insect living in organized colonies; characteristically the males and fertile queen have wings during breeding season; wingless sterile females are the workers (同)emmet, pismire
PrepTutorEJDIC
- 《話》(特定の慣習・政策・行動などに)反対する人
- 『アリ』
- =ain't
- certificate of deposit / (また『C.D.』)Civil Defense民間防衛
- (次にくる語の発音が母音で始まるときに用いる) / (子音[h]で始まり第1音節に強勢のない語の場合はanを用いることがある.ただし,この場合は[h]を発音しない)
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 症候性または進行した慢性リンパ性白血病に対する初期治療の選択 selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia
- 2. 移植片対宿主病の予防および治療に使用される免疫抑制剤の概要 overview of immunosuppressive agents used for prevention and treatment of graft versus host disease
- 3. T細胞性前リンパ性白血病の治療 treatment of t cell prolymphocytic leukemia
- 4. 移植後リンパ球増殖性疾患の疫学、臨床症状、および診断 epidemiology clinical manifestations and diagnosis of post transplant lymphoproliferative disorders
- 5. 化学療法による好中球減少症を有する成人のリスク評価 risk assessment of adults with chemotherapy induced neutropenia
English Journal
- Anti-tumor effects of anti-T-cell globulin.
- Westphal S1, Brinkmann H1, Kalupa M1, Wilke A1, Seitz-Merwald I2, Penack O3.
- Experimental hematology.Exp Hematol.2014 Oct;42(10):875-82. doi: 10.1016/j.exphem.2014.07.260. Epub 2014 Jul 10.
- In vivo T-cell depletion using anti-T-cell antibodies is a standard procedure during allogeneic hematopoietic stem cell transplantation (allo-HSCT). Clinical data demonstrate that in vivo T-cell depletion with the anti-CD52 monoclonal antibody Alemtuzumab is associated with increased relapse rates
- PMID 25017629
- Rationale and efficacy of CD52 targeting in HTLV-1-associated myositis.
- Cochereau D1, Georgin-Lavialle S2, Maisonobe T3, Dubourg O3, Melboucy-Belkhir S4, Hermine O5, Aouba A6.
- Joint, bone, spine : revue du rhumatisme.Joint Bone Spine.2014 Jul;81(4):362-5. doi: 10.1016/j.jbspin.2014.01.019. Epub 2014 Apr 4.
- We retrospectively analysed two selected patients, referred to our Haematology Department for refractory HTLV-1 associated myositis with circulating pathologic T-cell population with ATL phenotype. They respectively presented also HTLV-1 associated Crohn-like disease and myelopathy. Muscle biopsy of
- PMID 24709000
- Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia.
- Le Jeune C1, Thomas X.
- European journal of haematology.Eur J Haematol.2014 Jun 30. doi: 10.1111/ejh.12408. [Epub ahead of print]
- Targeted therapies represent a major breakthrough in the treatment of adult acute lymphoblastic leukaemia (ALL). Because lymphoblastic leukaemia cells express a variety of specific antigens, those ones can serve as targets for monoclonal antibodies (MoAbs). Anti-CD20 (rituximab), anti-CD19 (blinatum
- PMID 24981395
Japanese Journal
- 抗CD20抗体薬と抗CD52抗体薬 (特集 抗体によるがん分子標的治療) -- (がん領域の抗体薬)
- 石澤 賢一
- 最新医学 69(3), 379-385, 2014-03
- NAID 40020007546
- Recent Advances in the Treatment of Progressive or Refractory Langerhans Cell Histiocytosis: A Pivotal Role of Hematopoietic Stem Cell Transplantation:A Pivotal Role of Hematopoietic Stem Cell Transplantation
- 工藤 寿子
- 日本小児血液学会雑誌 21(5/6), 281-288, 2007
- … The approach of less-toxic RIST with antibodies to the CD52, TNF-α and CD1a will be promising for the patients with progressive or refractory LCH in the near future. …
- NAID 130004345961
Related Links
- The present invention relates to novel humanised antibodies against human CD52 and their use in methods of treating or preventing human diseases. ... The present invention relates to novel humanised antibodies against ...
- This patent application is assigned to Antitope Limited. The following quote was obtained by the news editors from the background information supplied by the inventors: "CD52 is a glycosylated, glycosylphosphatidylinositol (GPI)-anchored cell surface protein found in abundance on a variety of normal and ...
Related Pictures
![Anti-CD52 antibody [HI186] (ab2576](https://1mg.info/0/c/i/1460.jpg)
★リンクテーブル★
| 関連記事 | 「CD5」「CD」「ant」「anti」 |
「CD5」
- 同
- Leucine-1
発現細胞
- 胸腺細胞、T細胞、B細胞のサブセット (IMM)
- 胸腺細胞、T細胞、NK細胞、B1(B細胞のsubpopulation) (WCH.31)
- 成熟T細胞、胸腺細胞、一部のB細胞(CD5陽性B細胞(B-1細胞)。脾臓等、異所由来(骨髄非依存性)のB細胞) (資料1)
- B細胞性白血病・リンパ腫(資料1)
分子量
- 67kDa
別名
- T1, Ly1
機能
- CD5に対するモノクローナル抗体を作用させると、細胞内のチロシンのリン酸化が起こり、T細胞が活性化する。ただし、抑制的に作用する経路にも作用するかもしれない(WCH.31)
- T細胞はnaive CD4 T cellで発現しており、この細胞のマーカーとなる(IMM.315)
- CD5+ B細胞は自己抗体を産生する(WCH.31)
- CD72はCD5にたいするcounter-receptorである(WCH.31)
臨床関連
- B-CLLの多くの症例で発現している。 (WCH.31)
- 関節リウマチでCD5+ B細胞が増加する (WCH.31)
- 白血病/リンパ腫の中でCD5 positiveになるのは、慢性リンパ性白血病とマントル細胞リンパ腫だけ(HIM.693, 慢性リンパ性白血病#細胞表面マーカー WCH.2438)
参考
- 1. SRL
- 2. beckman
- 3. wiki en
「CD」
「ant」
- n.
- 同
- ants, stinging
「anti」
- comb form.